Analysis of 25 Up-and-Coming Cardiovascular Franchises
COMPLETED
This groundbreaking study gives market and strategic planners a thorough overview of companies that may have significant impact on the cardiovascular marketplace. It is an excellent tool for:
Identifying and qualifying development partners, licensing opportunities and acquisition targets
Understanding competitive threats
Over the next five years many new cardiovascular drugs will enter the market. Some will come from the biotechnology sector, some will come from major pharmaceutical companies that do not currently have a presence in cardiology, and some will come from foreign organizations not currently on the radar screen.
This study provides a thorough overview of the potential opportunities presented by these up-and-coming franchises as well as an understanding of the potential threats to current market share.
The targeted companies are analyzed from the following perspectives:
 | Current product portfolio |
| Cardiovascular pipeline |
| Key agreements/alliances |
| Sales and marketing capabilities |
| Research and clinical development capabilities |
| Financial and managerial resources |
| Strengths and weaknesses |
| Overall assessment |
* Save 5% -- Mention "PharmCast.com" when purchase.
To receive more information about the study, including a list of companies analyzed and sample pages, click on the "Request for Info" link.
 |
 |
| [
Outsourcing Guide
] [
Cont. Education
] [
Software/Reports
] [
Training Courses ]
[ Web Seminars ] [ Jobs ] [ Consultants ] [ Buyer's Guide ] [ Advertiser Info ] [ Home ] [ Pharm Patents / Licensing ] [ Pharm News ] [ Federal Register ] [ Pharm Stocks ] [ FDA Links ] [ FDA Warning Letters ] [ FDA Doc/cGMP ] [ Pharm/Biotech Events ] [ Newsletter Subscription ] [ Web Links ] [ Suggestions ] [ Site Map ] |